BridgeBio CEO Neil Kumar at BIO22 (J.T. MacMillan Photography for Endpoints News)
July 14, 2023 05:53 PM EDTUpdated July 17, 06:12 AM
R&D

Bridge­Bio's make-or-break read­out is slat­ed for Mon­day, as CEO posts a cryp­tic mes­sage about Odysseus

Kyle LaHucik

Senior Reporter

Drew Armstrong

Executive Editor

Bridge­Bio said it would share da­ta on a crit­i­cal Phase III tri­al on Mon­day morn­ing, in what’s ex­pect­ed to be a make-or-break mo­ment for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times